Legal & General Group
NVCT icon

Legal & General Group’s Nuvectis Pharma NVCT Stock Holding History

Legal & General Group’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.5K Buy
1,661
+489
+42% +$5.47K ﹤0.01% 2940
2026
Q1 		$9.06K Sell
1,172
-262
-18% -$2.24K ﹤0.01% 3203
2025
Q4 		$10.8K Hold
1,434
– – ﹤0.01% 3229
2025
Q3 		$8.63K Hold
1,434
– – ﹤0.01% 3318
2025
Q2 		$10.7K Buy
+1,434
New +$13K ﹤0.01% 3270
2024
Q2 		– Sell
-841
Closed -$6.9K – 3478
2024
Q1 		$6.9K Hold
841
– – ﹤0.01% 3258
2023
Q4 		$7.01K Hold
841
– – ﹤0.01% 3282
2023
Q3 		$10.8K Hold
841
– – ﹤0.01% 3251
2023
Q2 		$13.4K Buy
+841
New +$13.4K ﹤0.01% 3262

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Legal & General Group's NVCT Position: Q2 2026 in Review

Legal & General Group increased its Nuvectis Pharma (NVCT) stake by 42% in Q2 2026, buying an estimated $5.47K and bringing the position to 1,661 shares worth $30.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2940.

Legal & General Group first reported a position in NVCT in Q2 2023 and has held it in 9 quarters since. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Legal & General Group held 1,661 shares of Nuvectis Pharma worth $30.5K as of Q2 2026.
  • Legal & General Group bought 489 Nuvectis Pharma shares in Q2 2026, an estimated $5.47K.
  • Nuvectis Pharma made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2940 holding.
  • Legal & General Group first reported a position in Nuvectis Pharma in Q2 2023 and has held it in 9 quarters since.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.